DRUG
LY3437943
Administered SC
Status
Completed
Phase
Phase 1
Enrollment
85
Locations
3
Results
Not posted
Publications
0
Study summary
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
Interventions
DRUG
Administered SC
OTHER
Administered SC
Timeline
First posted
Mar 15, 2024
Study start
Mar 20, 2024
Primary completion
Aug 26, 2025
Study completion
Aug 26, 2025
Results posted
Not reported
Registry updated
Sep 23, 2025
Outcomes
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Time frame · Baseline up to Week 17 (inclusive)
Change from Baseline in Sleep Metabolic Rate (SMR)
Time frame · Baseline up to Week 16 (inclusive)
In participants who achieve target weight loss
Change from Baseline in SMR
Time frame · Baseline up to Week 16 (inclusive)
Change from Baseline in 24-hour Energy Expenditure (EE)
Time frame · Baseline up to Week 16 (inclusive)
In participants who achieve target weight loss
Change from Baseline in 24-hour EE
Time frame · Baseline up to Week 16 (inclusive)
Change from Baseline in Total Calorie Intake at Lunch
Time frame · Baseline up to Week 17 (inclusive)
Change from Baseline in Total Calorie Intake at Dinner
Time frame · Baseline up to Week 17 (inclusive)
Change from Baseline in Fasting Appetite Visual Analog Score (VAS)
Time frame · Baseline up to Week 16 (inclusive)
Eligibility
Inclusion Criteria: * BMI greater than 30 kg/m2 * History of at least 1 self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study * Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty * Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity * Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state * Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2 * Acute or chronic hepatitis * Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure * History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior * History of chronic or acute pancreatitis * Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia * Clinically significant multiple or severe drug allergies * Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain * History of substance use disorder
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
AdventHealth Orlando
Orlando, Florida, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Columbia University Irving Medical Center
New York, New York, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.